Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.57 |
| ▸ | FADS1 | O60427 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 2/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 7/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27604456 | 0.76 | TRPA1 (0.71) | TRPA1FADS1GRM4ADRA2A | |
| SCHEMBL4741513 | 0.75 | TRPA1 (0.75) | TRPA1FADS1GRM4ADRA2AEGFR | |
| SCHEMBL29882003 | 0.75 | TRPA1 (0.75) | TRPA1FADS1GRM4ADRA2AEGFR | |
| SCHEMBL4828265 | 0.75 | EPHX2 (0.58) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1129188 | 0.74 | LPL (0.65) | CA12CA1CA2CA3CA4 | |
| SCHEMBL1104787 | 0.73 | KDM4E (0.43) | TRPA1LPLLIPGAURKA | |
| SCHEMBL29592533 | 0.73 | TRPA1 (0.71) | TRPA1FADS1GRM4ADRA2AEGFR | |
| SCHEMBL4822088 | 0.73 | TRPA1 (0.71) | TRPA1FADS1GRM4ADRA2AAURKA | |
| SCHEMBL2380323 | 0.72 | PRMT5 (0.42) | CA12CA1CA2CA3CA4 | |
| SCHEMBL7346388 | 0.71 | TRPA1 (0.69) | TRPA1FADS1GRM4ADRA2AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7400979-B2 | Kinase inhibitors; genetic engineering | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | ABBVIE INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003020880-A2 | METHOD OF IDENTIFYING INHIBITORS OF LCK | ABBOTT LABORATORIES (US) | 2003-03-13 | — | — | WO | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | TRPA1 2644/4885FADS1 4541/4885GRM4 1631/4885 |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | LCK, FYN, ZAP70 | TRPA1 3517/4885FADS1 3456/4885GRM4 4250/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | TRPA1 2676/4885FADS1 4524/4885GRM4 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.